LQDA stock forecast, quote, news & analysis

Key Takeaways

• Liquidia's YUTREPIA generated $148.3 million in preliminary full-year 2025 net sales, with $90.1 million in Q4 alone, driving over $30 million in positive cash flow.
• Over 2,800 unique patient prescriptions and an 85% conversion rate highlight strong commercial uptake since the June 2025 launch.
• Analysts maintain a Moderate Buy consensus with an average price target around $40, supported by recent upgrades like Jefferies to $55.
• Pipeline advancements, including L606 and data presentations at PVRI 2026 Congress, signal expansion into new indications like IPF and PH-COPD.
• Ongoing litigation with United Therapeutics remains a key risk amid robust YUTREPIA growth.

Current Market Snapshot

Liquidia Corporation (LQDA) has shown strong momentum in recent trading sessions, buoyed by the successful commercialization of its lead product YUTREPIA for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The stock has traded within a wide 52-week range, reflecting volatility tied to regulatory milestones and sales ramps, while market capitalization hovers around $3.5 billion. Investor sentiment remains positive amid positive cash flow generation and expanding prescriber base, though broader biotech sector pressures and competitive dynamics in inhaled prostacyclins warrant close monitoring. Recent sessions underscore sustained demand for YUTREPIA, positioning LQDA as a standout in the pulmonary therapeutics space.

Recent Developments Driving LQDA Price Action

Liquidia Corporation (LQDA) has experienced significant price appreciation in recent weeks, driven by robust commercial performance of its flagship inhaled therapy YUTREPIA (treprostinil inhalation powder). On January 9, 2026, the company released preliminary unaudited financials revealing full-year 2025 YUTREPIA net product sales of approximately $148.3 million, including a standout $90.1 million in the fourth quarter. This marked over 2,800 unique patient prescriptions since the June 2025 launch following FDA approval on May 23, 2025, with more than 2,200 patients initiated and an impressive 85% prescription-to-start conversion rate through November. Notably, Q4 generated more than $30 million in positive cash flow, bolstering the balance sheet to $190.7 million in cash equivalents by year-end. These figures exceeded expectations, fueling a 14.2% stock surge shortly after the announcement as investors digested the rapid path to profitability in the first full launch quarter.

Earlier momentum stemmed from Q3 2025 results reported in November, where net product sales hit $51.7 million, achieving operating income of $1.7 million and adjusted EBITDA of $10.1 million. Over 2,000 unique prescriptions and 1,500 patient starts underscored prescriber adoption, reaching around 750 physicians. This profitability shift from prior losses enhanced confidence, contributing to shares nearing 52-week highs above $46.

Analyst actions amplified the upward trajectory. Jefferies raised its price target to $55 from $45 on January 13, 2026, citing YUTREPIA's momentum, while Zacks upgraded to Strong Buy. Consensus holds at Moderate Buy from 11 analysts, with targets averaging $39.67, though highs reach $55. Laughing Water Capital highlighted LQDA positively in its Q4 letter, and Zacks noted momentum strength.

On January 27, 2026, Liquidia announced three poster presentations at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress, covering interim and open-label data for YUTREPIA (LIQ861) and L606 across PAH, PH-ILD, and exploratory indications. This reinforced pipeline differentiation via the PRINT technology for superior lung delivery and tolerability versus competitors like Tyvaso.

However, sentiment incorporates risks from ongoing patent litigation with United Therapeutics over inhaled treprostinil exclusivity, potentially impacting market access. Insider sales, including by executives, have occurred amid the rally, though tied to option exercises. Macro factors like payer negotiations and biotech funding environment also influenced volatility, but YUTREPIA's execution has dominated, linking directly to price gains exceeding 25% in the past 30 days.

2026 Outlook and Key Factors to Monitor

As Liquidia enters 2026, focus sharpens on scaling YUTREPIA commercialization while advancing its pipeline amid a transition to sustained profitability. Analysts project EPS growth exceeding 496% year-over-year, with FY2026 estimates averaging $2.69, reflecting anticipated revenue expansion from deepened market penetration in PAH and PH-ILD. Peak sales forecasts for YUTREPIA now range $1.7-2 billion long-term, supported by manufacturing capacity tripling via a new North Carolina facility.

Key themes include clinical data readouts from PVRI Congress and further studies differentiating YUTREPIA's rapid titration and tolerability. L606, the twice-daily liposomal treprostinil inhalation suspension licensed from Pharmosa Biopharm, targets pivotal trials for expanded indications like idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and PH-COPD, addressing unmet needs in prostacyclin therapies.

Opportunities lie in sales force expansion, payer access improvements, and global partnerships, potentially establishing new standards in inhaled prostacyclins. Risks encompass litigation outcomes with United Therapeutics, pricing pressures, competition from Tyvaso, and execution on clinical milestones. Regulatory considerations for L606 and manufacturing scale-up remain critical, alongside macroeconomic biotech trends and debt management (debt-to-equity over 800%). Investors should track Q4 earnings in March 2026 for formal guidance, balancing robust 2025 momentum against these factors.